Updated Jul 16, 2026
Girao Tiago has filed 2 SEC Form 4 filings across 1 company in the last 90 days — selling. Lifetime open-market sales: $1.15M.
Tiago Girao is the Chief Financial Officer at Immunovant, Inc., a company focused on developing innovative therapies for autoimmune diseases. His role involves overseeing the financial operations and strategic financial planning of the company.
| Role | Chief Financial Officer |
|---|---|
| Notability | 10/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-06-26 | IMVT | Immunovant, Inc. | S — Open-market sale | 10.0K | $38.46 | $385K |
| 2026-06-26 | IMVT | Immunovant, Inc. | M — Option exercise | 10.0K | $15.90 | $159K |
| 2026-04-24 | IMVT | Immunovant, Inc. | S — Open-market sale | 25.8K | $29.62 | $763K |
| 2026-04-09 | IMVT | Immunovant, Inc. | A — Grant or award | 65.0K | $0.00 |
Tiago Girao is the Chief Financial Officer at Immunovant, Inc., a company focused on developing innovative therapies for autoimmune diseases. His role involves overseeing the financial operations and strategic financial planning of the company.…
2 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 0 open-market purchases () and 2 open-market sales ($1.15M) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Girao Tiago profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.